Codexis, Inc.

Equities

CDXS

US1920051067

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 18/05/2024 am IST			5-day change	1st Jan Change
3.61 ^USD	-4.24%		-0.28%	+18.36%

14/05	Codexis, Inc. Presents Enzymatic Synthesis Data at TIDES USA Annual Meeting and Launches RNA Ligase Screening and Optimization Services	CI
02/05	Earnings Flash (CDXS) CODEXIS Posts Q1 Revenue $17.1M, vs. Street Est of $13.3M	MT

Codexis, Inc. Reiterates Financial Guidance for the Fiscal 2024

May 03, 2024 at 01:35 am IST

Codexis, Inc. reiterated financial guidance for the fiscal 2024. For the period, the company product revenues are expected to be in the range of $38 million to $42 million, excluding revenue related to PAXLOVID?. R&D revenues are expected to be in the range of $18 million to $22 million.

Latest news about Codexis, Inc.

Codexis, Inc. Presents Enzymatic Synthesis Data at TIDES USA Annual Meeting and Launches RNA Ligase Screening and Optimization Services	14/05	CI
Earnings Flash (CDXS) CODEXIS Posts Q1 Revenue $17.1M, vs. Street Est of $13.3M	03/05	MT
Transcript : Codexis, Inc., Q1 2024 Earnings Call, May 02, 2024	03/05
Codexis, Inc. Reiterates Financial Guidance for the Fiscal 2024	03/05	CI
Codexis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05	CI
Codexis, Inc. Appoints Carole Cobb to Its Strategic Advisory Board	11/04	CI
Benchmark Upgrades Codexis to Buy From Hold, Price Target is $9	29/02	MT
Transcript : Codexis, Inc., Q4 2023 Earnings Call, Feb 28, 2024	29/02
Earnings Flash (CDXS) CODEXIS Reports Q4 Revenue $26.6M, vs. Street Est of $18.9M	29/02	MT
Codexis, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02	CI
Codexis Shares Up 31% on Roche Licensing Agreement	27/02	DJ
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche	27/02	CI
Roche Sequencing Solutions, Inc. entered into an agreement to acquire Global license of double-stranded DNA from Codexis, Inc.	26/02	CI
Codexis, Inc Appoints Masad Damha, PhD and Jim Lalonde, PhD to Strategic Advisory Board	20/02	CI
Codexis, Inc. Announces Not to Stand for Reelection of Jennifer Aaker as Board of Director	17/02	CI
Transcript : Codexis, Inc. - Special Call	14/02
Codexis, Inc. Enters into Loan and Security Agreement with Innovatus Life Sciences Lending Fund I, LP	14/02	CI
Codexis, Inc. announced that it expects to receive $40 million in funding	13/02	CI
SeqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting	02/02	CI
Swiss Shares Decline Amid Lingering Concerns for Growth of Local Economy	27/12	MT
Nestlé Unit to Buy Codexis’ Pancreatic Condition Therapy for Up to $45 Million	27/12	MT
Codexis, Inc. Announces Purchase Agreement with Nestle Health Science for Cdx-7108	27/12	CI
Codexis Assigns Interests in Potential Exocrine Pancreatic Insufficiency Treatment to Nestle Health Science	27/12	MT
Codexis, Inc.(NasdaqGS:CDXS) dropped from NASDAQ Biotechnology Index	15/12	CI
Top Midday Gainers	15/12	MT

Chart Codexis, Inc.

Duration

Period

More charts

Company Profile

Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.

Sector

Biotechnology & Medical Research

Calendar

21/05/2024 - Benchmark Healthcare House Virtual Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Codexis, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.61 USD

Average target price

6.571 USD

Spread / Average Target

+82.03%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CODEXIS, INC.	+18.36%	27Cr
MODERNA, INC.	+33.63%	5.08TCr
IQVIA HOLDINGS INC.	-0.09%	4.28TCr
LONZA GROUP AG	+49.62%	4.2TCr
CELLTRION, INC.	-4.96%	2.95TCr
ICON PUBLIC LIMITED COMPANY	+11.18%	2.61TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	1.91TCr
BIO-TECHNE CORPORATION	+8.61%	1.31TCr
MEDPACE HOLDINGS, INC.	+28.31%	1.22TCr
UNITED THERAPEUTICS CORPORATION	+24.73%	1.21TCr

Other Biotechnology & Medical Research